Problem

Juno addresses the fragmented, exhausting work of living with chronic illness. More than 1 billion people live with conditions such as fibromyalgia, long COVID, POTS, ME/CFS, EDS, endometriosis, lupus, and MS; patients may wait months for an appointment and then have only 15 minutes to explain years of symptoms. The average diagnosis reportedly takes 7.6 years, while general-purpose AI tools such as ChatGPT and Claude lack the longitudinal context needed to give consistently actionable guidance. The practical cost is lost time, energy, and clinical context, compounded by isolation and the burden of manually tracking symptoms, medications, flares, and appointments.

The core use case is helping someone turn day-to-day experience into something useful for care. During a flare—or even at 3 a.m.—a user can talk through what is happening instead of filling out forms, then use the accumulated record to prepare for a doctor visit. Juno’s most compelling promise is to reduce the effort of remembering and explaining a complex health history while helping users feel heard between appointments.

Product / Service

Juno is a mobile, AI-powered health and wellness companion available through app stores. Users interact by text or voice, and Juno builds a longitudinal profile from conversations, biometrics, medical history, and symptom records. It can automatically capture symptoms and energy levels, identify patterns and possible triggers over weeks or months, remember prior context, and support pacing and daily planning. It also converts the accumulated information into a concise, doctor-ready report with timelines covering symptoms, flares, sleep, medication changes, and what helps.

The service uses a free-to-download model with paid Juno Pro subscriptions; the terms list Pro at $19.99 per month or $99.99 per year, with local store pricing potentially varying. The benefit is lower-friction tracking and better-prepared appointments rather than another manual diary. Juno explicitly positions itself as a general wellness companion, not a medical device or substitute for a clinician: it does not provide diagnosis, treatment, therapy, or medical advice, and its reports are intended to support—not replace—clinical judgment.

Market

Juno competes in consumer health and wellness at the intersection of AI health assistants, chronic-condition self-management, symptom tracking, and emotional support. Its substitutes include general-purpose AI assistants such as ChatGPT and Claude, while more directly positioned alternatives identified in the market include Docus.ai, Remy AI, and March Health; Flaredown is an adjacent chronic-illness symptom-tracking and community product. Juno differentiates through chronic-illness-specific memory, conversational logging, pattern detection, and doctor-facing summaries rather than one-off health answers or a conventional symptom diary.

Juno is not pre-revenue. Its Y Combinator company profile says the product launched in October and supports more than 150,000 patients globally; the App Store shows a 4.8 rating from approximately 9,200 ratings. Other launch snapshots report 125,000-plus patients and $80,000 in monthly recurring revenue, while an earlier Y Combinator launch post cited 80,000 users and more than 9,000 five-star reviews. The differing figures appear to be dated snapshots, but together with the paid subscription model they indicate substantial early consumer traction and active monetization.